Samsung Biologics Quarterly Profit Jumps – Key Margin Insights Samsung Biologics is a Buy: operating profit rose 39.7% despite revenue decline, but labor disputes may create volatility until next-quarter results confirm stabilization. 2026년 05월 21일 English
Samsung Biologics Labor Unrest Fears Ease: Profit Resilience Samsung Biologics is rated Buy: labor unrest threatens production, but latest results show operating profit and net income growth despite revenue collapse, suggesting the stock’s risk discount may be excessive. 2026년 05월 05일 English
